Novavax (NVAX) has been struggling to convince the market that its COVID era gains can translate into a durable vaccine business, and the stock’s recent slide reflects those doubts. See our latest ...
Novavax’s alliance with Sanofi came at an opportune time for the beleaguered vaccine developer. Its protein-based Covid-19 vaccine never reached the revenue highs achieved by the messenger RNA ...
The Food and Drug Administration (FDA) signed off Wednesday on an emergency use authorization for the Novavax COVID-19 vaccine for individuals 18 years of age and older. The Novavax vaccine is ...
Novavax, Inc. recently announced at the Jefferies London Healthcare Conference 2025 that it is shifting its focus from direct COVID-19 commercial operations to an expanded research and development ...
A medical worker prepares ampoules of the Nuvaxovid vaccine against Covid-19 by Novavax at the Tegel vaccination center on February 28, 2022 in Berlin, Germany. This story was originally published ...
The Biden administration announced Monday that it would purchase 3.2 million doses of the Novavax COVID-19 vaccine. It will be offered at no cost to states and federal partners. “We remain ...
NEW YORK -- The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across ...
A spokesman for Moderna, which makes Covid vaccines, pointed to a September statement saying the company didn’t know of any ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback